risks of glp 1 agonists The promise and peril GLP-1 agonists: What we do (and don't) know as of August 2024 The Role of GLP-1RA Medications

Here's how it works

veterans with type 2 diabetes for three years

Simonsen et al used the Norwegian and Danish national health registries and found an increased risk of NAION development with semaglutide initiation (HR = 2.81)

There is no clinical data on this combination, and it is generally not recommended because the GLP-1 receptor activation from multiple compounds would overlap, potentially increasing gastrointestinal side effects without proportional benefit

Lisa J Moran, Monash Centre for Health Research and Implementation, Monash University and Monash Health, Melbourne, Victoria, Australia

This marker is sort of a broad marker of systemic inflammation